$14.11
2.22%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
US78349D1072
Symbol
RXST

RxSight Inc Stock price

$14.43
-12.07 45.55% 1M
-35.60 71.16% 6M
-19.95 58.03% YTD
-38.40 72.69% 1Y
+1.66 13.00% 3Y
-1.57 9.81% 5Y
-1.57 9.81% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.10 0.65%
ISIN
US78349D1072
Symbol
RXST
Sector

Key metrics

Market capitalization $584.28m
Enterprise Value $359.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.57
P/S ratio (TTM) P/S ratio 4.18
P/B ratio (TTM) P/B ratio 2.07
Revenue growth (TTM) Revenue growth 57.08%
Revenue (TTM) Revenue $139.93m
EBIT (operating result TTM) EBIT $-36.86m
Free Cash Flow (TTM) Free Cash Flow $-22.39m
Cash position $237.22m
EPS (TTM) EPS $-0.71
P/E forward negative
P/S forward 3.43
EV/Sales forward 2.11
Short interest 8.14%
Show more

Is RxSight Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

RxSight Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a RxSight Inc forecast:

5x Buy
45%
4x Hold
36%
2x Sell
18%

Analyst Opinions

11 Analysts have issued a RxSight Inc forecast:

Buy
45%
Hold
36%
Sell
18%

Financial data from RxSight Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
140 140
57% 57%
100%
- Direct Costs 41 41
16% 16%
29%
99 99
84% 84%
71%
- Selling and Administrative Expenses 98 98
39% 39%
70%
- Research and Development Expense 34 34
18% 18%
25%
-33 -33
28% 28%
-24%
- Depreciation and Amortization 3.62 3.62
15% 15%
3%
EBIT (Operating Income) EBIT -37 -37
26% 26%
-26%
Net Profit -27 -27
44% 44%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about RxSight Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RxSight Inc Stock News

Negative
Seeking Alpha
18 days ago
RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was premature. The competitive landscape has intensified with new IOL products from Johnson & Johnson and Rayner, challenging RxSight's unique LAL technology.
Neutral
Seeking Alpha
18 days ago
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Preliminary Results Conference Call April 3, 2025 8:00 AM ET Company Participants Oliver Moravcevic - VP, IR Dr. Ron Kurtz - Director, Co-President and CEO Shelley Thunen - Assistant Secretary, Co-President and CFO Conference Call Participants Ryan Zimmerman - BTIG Xuyang Li - Jefferies Robert Marcus - JPMorgan Steve Lichtman - Oppenheimer David Saxon - Need...
Neutral
GlobeNewsWire
19 days ago
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2...
More RxSight Inc News

Company Profile

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Head office United States
CEO Ronald Kurtz
Employees 498
Founded 1997
Website rxsight.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today